Epigenetics and therapeutic targets in gastrointestinal malignancies
Authors:
- 1 October 2021
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (10) , 2303-2314
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- LINE-1 Hypomethylation Is Associated With a Poor Prognosis Among Patients With Curatively Resected Esophageal Squamous Cell CarcinomaAnnals of Surgery, 2013
- Oncogene Ras/Phosphatidylinositol 3-Kinase Signaling Targets Histone H3 Acetylation at Lysine 56Journal of Biological Chemistry, 2012
- A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's EsophagusCancer Research, 2009
- Overexpression of SIRT1 Protects Pancreatic β-Cells Against Cytokine Toxicity by Suppressing the Nuclear Factor-κB Signaling PathwayDiabetes, 2009
- A Cohort Study of Tumoral LINE-1 Hypomethylation and Prognosis in Colon CancerJNCI: Journal of the National Cancer Institute, 2008
- Genomic and Epigenetic Instability in Colorectal Cancer PathogenesisGastroenterology, 2008
- Nickel compounds induce phosphorylation of histone H3 at serine 10 by activating JNK-MAPK pathwayCarcinogenesis, 2008
- Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancerProceedings of the National Academy of Sciences, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Colorectal cancer: a model for epigenetic tumorigenesisGut, 2006